6505--Humatin 250mg Medication IDIQ FY 26

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

257-NETWORK CONTRACT OFFICE 17 (36C257)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36C25726Q0011

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The 257-Network Contract Office 17 (36C257), a federal contracting entity, has issued a solicitation for an Indefinite Delivery Indefinite Quantity (IDIQ) contract for the supply of Humatin 250mg medication, under procurement identifier 36C25726Q0011. This opportunity is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and carries the Product Service Code 6505, indicating a focus on drugs and biologicals. The primary objective of this procurement is to ensure the availability of Humatin 250mg capsules in 100-count bottles for patient-specific needs within the contracting office’s service area. The contract is structured as an IDIQ, allowing for flexible ordering based on actual patient requirements. While there are currently no active prescriptions for Humatin, the demand is subject to change and the medication will be ordered only when needed for individual patients. The scope of the contract specifies a minimum order quantity of 2 bottles and a maximum of 5 bottles per year. This range reflects the anticipated but variable demand, ensuring that the contracting office can respond promptly to patient needs without overcommitting resources. Contractors should note that orders will be placed on an as-needed basis, and the medication is not stocked in advance. Key deliverables for this contract include the timely supply of Humatin 250mg capsules in accordance with patient-specific requests, adhering to the defined annual minimum and maximum quantities. The contract period of performance (PoP) will be determined at the time of award, with an estimated start date following the conclusion of the solicitation process. The solicitation is currently active, with the official post date of March 11, 2025. Interested vendors should be aware of the updated response timeline: questions regarding the solicitation are due by October 27, 2025, and the final quote submission deadline has been extended to November 14, 2025, at 20:11. All communications and submissions should be directed to the primary contact, Tammy L Wilson, at [email protected]. This procurement does not specify any set-aside requirements or special considerations beyond the patient-specific nature of the orders and the defined quantity limits. Contractors with capabilities in pharmaceutical preparation manufacturing, particularly those able to reliably supply Humatin 250mg capsules in the required packaging and quantities, are encouraged to review the solicitation details and attachments available on SAM.gov (Opportunity ID: a82633e2d35c430da47750d83d1527a5). In summary, this opportunity offers a stable, patient-driven supply contract for Humatin 250mg medication, with clear annual quantity parameters and a responsive ordering process. It is well-suited for vendors experienced in fulfilling small-batch, on-demand pharmaceutical orders for federal healthcare entities.